

Substitute for form 1449A/PTO				Application Number	Unassigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Filing Date	03/30/2006
				First Named Inventor	Wilfried Lubisch et al.
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	2	Attorney Docket No.	ABB10010P0912US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
/N.C./		US- 5,594,023	01/14/1997	Sanofi	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/N.C./		WO 01/98295 A1	12/27/2001	Sanofi-Synthelabo		
		WO 01/55134 A2	08/02/2001	Sanofi-Synthelabo		
		WO 01/55130 A2	08/02/2001	Sanofi-Synthelabo		
		WO 01/64668 A2	09/07/2001	Sanofi-Synthelabo		
		WO 03/008407 A2	01/30/2003	Sanofi-Synthelabo		
		WO 98/25901	06/18/1998	Sanofi		
		WO93/15051	08/05/1993	Elf Sanofi		
/N.C./		WO 95/18105	07/06/1995	Sanofi		
Examiner Signature		/Nizal Chandrakumar/			Date Considered	08/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Application Number	8104574211
	Filing Date	03/30/2006
	First Named Inventor	Wilfried Lubisch et al.
	Group Art Unit	Unknown
	Examiner Name	Unknown
	Attorney Docket No.	ABB10010P0912US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/N.C./		BARBERIS, et al., Structural bases of vasopressin/oxytocin receptor function, > Endocrinology, 1998, 223-229, Vol. 156, France	
/N.C./		HULME, et al., Quaternary Substituted PDE4 Inhibitors I: The synthesis and In Vitro Evaluation of a Novel Series of Oxindoles, Bioorg. & Med. Chem. Lett, 1998, 175-178, Vol. 8, United Kingdom	
/N.C./		WERSINGER, et al., Vasopressin V1b receptor knockout reduces aggressive behavior in male mice, Molecular Psychiatry, 2002, 975-984, Vol. 7, United Kingdom	
/N.C./		GRIEBEL, et al. Anxiolytic- and antidepressant-like effects of the nonpeptid vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders, PNAS, 2002, 6370-6375, Vol. 99, France	
/N.C./		SERRADEIL-LE GAL, et al., J. Pharm. Exp. Ther., 2002, 1122-1130, Vol. 300, France	
Examiner Signature	/Nizal Chandrakumar/		Date Considered 08/11/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.